The flying cars market is gaining traction, with companies making steady progress toward making electric vertical takeoff and landing vehicles (eVTOLs) commercially available. Certifications from regulatory authorities like the FAA boost confidence in this transformative sector, presenting investors with a potential opportunity. However, just because an industry is on the rise doesn’t mean all companies

In recent months, tech stocks have consistently captured investors’ attention as a result of explosive advancements in Artificial Intelligence (AI) and an ever-evolving semiconductor industry. These developments have ignited fierce growth and innovation across the sector, bringing numerous tech companies into the spotlight. Despite this buzz, there is a palpable sense of fear among some

Many cheap stocks under $10 are cheap for a good reason. Cash-burning biotechs, sketchy shell companies and overhyped fads with more sizzle than substance. But amidst the minefield of duds, there are always a few diamonds in the rough with legitimate 10-bagger potential. I’ve sifted through the bargain bin to bring you seven of the

Understanding the fundamentals of companies is crucial when evaluating stocks to buy. These stocks remain undervalued and are industry leaders with strong growth potential, positioning them to significantly drive the market higher post-earnings season. To begin with, the first company excels in cybersecurity with an AI-driven, modular platform that offers significant cost savings and rapid

Although a controversial sector, the concept of top defense stocks will likely become an increasingly important one. Primarily, circumstances in the geopolitical realm will likely worsen. At the same time, a critical election cycle could mean significant changes. Therefore, emotionally agnostic investors may consider the potential viability of this ecosystem. Several worrying catalysts come to

Sometimes, the best deals on the market offer real growth potential and a decent dividend yield. That’s because these types of securities offer a dual-factor approach to appreciating by providing returns in stock growth and a compounding dividend. Yet, finding these types of dividend stocks under $10 can be challenging as the media often underreport

As the world accelerates its transition towards renewable energy, battery stocks remain at the forefront of this global shift. Heading into the summer of 2024, the demand for high-performance, sustainable battery solutions is more critical than ever. As per McKinsey & Company, the lithium-ion battery market is expected to grow to more than $400 billion

Investing in innovative companies can yield substantial returns, and Salesforce (NYSE:CRM) stock exemplifies this potential. As the world’s leading provider of customer relationship management (CRM) solutions, Salesforce has established itself as a dominant force in the enterprise software and cloud computing sectors. However, despite this impressive growth, the stock has experienced significant fluctuations this year,

Software stocks are some of the best investment options available for 2024 after a 28.2% gain in the technology sector drove them to excellent returns in the first half of the year. In the first half of 2024 the Nasdaq Composite Index, which is mostly weighted with technology and software stocks, rose by 18.6%. Over the

The Nasdaq Composite has been a solid benchmark for many years. It’s up by 16% year-to-date and has logged a 114% gain over the past five years. The index consists of numerous holdings but has a large focus on tech companies. The Magnificent Seven stocks, in particular, carry a lot of weight within the Nasdaq

Lithium prices are struggling at multi-year lows, forcing some miners to consider closing down mines and delaying projects. But I’d use that as a reason to buy beaten-down lithium stocks for the long term. After all, we’ve seen this play out before. In 2018, prices peaked due to oversupply, which led to a massive 60%

If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ:GPCR), for example. On March 8, I learned that GPCR would report Phase 2a 12-week obesity drug data in the second quarter of the year. Knowing that Phase 1 trials had positive results, I anticipated that Phase